GLP-1s and the ‘Wild West’ of Wellness

GLP-1 receptor agonists have transformed the landscape of weight management and metabolic health, offering a pharmaceutical intervention that effectively regulates appetite by signaling satiety through the brain. While originally approved for diabetes, these drugs demonstrate significant, weight-independent benefits, including reduced inflammation and potential protection against cardiovascular, kidney, and liver diseases. However, the rapid, widespread adoption of these medications—often fueled by algorithmic social media and telemedicine—raises concerns regarding long-term safety, the normalization of extreme body standards, and the emergence of unregulated biohacking practices. Addressing the underlying causes of metabolic disease requires shifting focus from individual willpower to systemic changes in the food environment, such as restricting junk food marketing and improving access to nutritious options, rather than relying solely on pharmaceutical solutions to mitigate the consequences of a toxic food system.